ShillaJen's Two BAL0891 Studies Selected for Presentation at Society for Immunotherapy of Cancer Annual Meeting

On October 15, ShillaJen announced that two studies on its anticancer drug candidate 'BAL0891,' currently under development, have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, which will be held in Maryland, USA, from November 7 to 9, 2025 (local time). The SITC is the world's largest academic society in the field of cancer immunotherapy, attended by global anticancer drug developers and leading researchers.

The selected studies on BAL0891 to be presented at SITC 2025 are as follows:

The first study investigated the synergistic effects of BAL0891, a dual inhibitor of TTK/PLK1, with immune checkpoint inhibitors (ICIs) by optimizing immune modulation using a tumor microenvironment platform and pharmacological modeling that mimic human tissues. The results clearly demonstrated a synergistic effect between BAL0891 and immune checkpoint inhibitors through combination simulation, and also identified the optimal timing for combination administration.

The second study introduces a phase 1 clinical trial combining BAL0891 with Tislelizumab (Anti-PD-1), an immune checkpoint inhibitor developed by the global pharmaceutical company BeiGene, in patients with advanced solid tumors. This trial is planned to enroll approximately 30 patients in the United States and South Korea. Based on previous studies and multiple preclinical results, a synergistic effect between the two drugs is anticipated.

Detailed results and findings from these two studies will be released at the upcoming SITC 2025 Annual Meeting next month.

A ShillaJen representative stated, "The selection of two BAL0891 studies by the Society for Immunotherapy of Cancer, one of the world’s most prestigious academic societies, was made possible by the ongoing efforts of our company and collaborating researchers. As there is significant academic interest in the combination of BAL0891 and immune checkpoint inhibitors, we will do our utmost to achieve positive results in the combination clinical trial with Tislelizumab and provide innovative cancer treatment options."

This content was produced with the assistance of AI translation services.